

PERSONAL INFORMATION**Vincenzo Ronca, MD – GMC number 7693775****RESEARCH WORK**

1/05/2019–Present

Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy University of Birmingham
Birmingham (UK)

01/12/2016–1/05/2019

Clinical and Research fellow at Division of Hepatology and Gastroenterology University of Milan-Bicocca School of Medicine
Monza (Italy)**CLINICAL WORK**

01/11/2015–Present

Specialist Registrar – Internal Medicine

- Queen Elizabeth Hospital, Birmingham UK – **Liver Unit (01/05/2019- present)**
- Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico, Milan - **Emergency Department (15/10/18 – 01/05/2019)**
- San Paolo University Hospital, Milan, Italy - **Department of Gastroenterology and Hepatology - Abdomen Ultrasound service (15/06-14/10/18)**
- Luigi Sacco Hospital - **Intensive Cardiology Unit Department (15/03-14/06/18)**
- San Paolo University Hospital, Milan, Italy - **Department of Nephrology (15/01-14/03/2018)**
- San Paolo University Hospital, Milan, Italy - **Department of Gastroenterology and Hepatology: Inpatients Unit of Internal Medicine; Outpatients Unit of Hepatology with particular interest in Autoimmune liver diseases and rare diseases (e.g. Wilson Disease) (1/11/2015-15/01/2018)**

EDUCATION AND TRAINING

01/11/2015–Present

Residency Program in Internal Medicine
University of Milan, Milan (Italy)

01/10/2008–31/07/2014

Medical Doctor

University of Pavia, Pavia (Italy)

Graduation thesis: "Prevalence and prognostic value of portal vein thrombosis in cirrhotic patient"

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C1	C2	C1	C1	C1

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

ADDITIONAL INFORMATION

Publications

Papers

1. **Ronca V**, Mancuso C, Milani C, Carbone M, Oo YH, Invernizzi P. Immune system and cholangiocytes: a puzzling affair in primary biliary cholangitis. *Journal of Leukocyte Biology*. *Accepted*
2. **Ronca V**, Chen Q B, Lygoura V, Ben-Mustapha I, Shums Z, Trifa M, Carbone M, Mancuso C, Milani C, Bernuzzi, F, Ma X, Agrebi N, Norman G L., Chang C, Gershwin ME, Barbouche M, Invernizzi P. Autoantibodies in patients with IL12 β 1 receptor deficiency. *Journal of Digestive Diseases*. 2019.
3. **Ronca V**, Gerussi A, Cristoferi L, Carbone M, Invernizzi P. Precision medicine in primary biliary cholangitis. *Journal of Digestive Diseases*. 2019
4. **Ronca V**, Podda GM, Cattaneo M. An "unmodifiable" risk factor that has been modified. *Internal and Emergency Medicine*. 2019
5. Cristoferi L, Nardi A, **Ronca V**, Invernizzi P, Mells G, Carbone M. Prognostic models in primary biliary cholangitis. *J Autoimmun*. 2018 Nov 9..
6. M. Carbone, A. Nardi, G. Carpino, M. Heneghan, D. Thorburn, S. Taylor-Robinson, A. Bathgate, M. Zuin, P.M. Battezzati, A. Floreani, E.G. Giannini, M.F. Donato, M. Marziani, D. Alvaro, L. Miele, F. Marra, H. Ainsworth, L. Muratori, G. Bonato, **Ronca V**, L. Cristoferi, D. Stocken, V. Cardinale, G. Hirschfield, G.J.M. Alexander, R. Sandford, D. Jones, P. Invernizzi, G. Mells. Pre-treatment risk stratification in primary biliary cholangitis: a predictive model to guide first-line combination therapy. *Lancet Gastroenterol Hepatol*. 2018 Sep
7. Muratori P, Carbone M, Stangos G, Perini L, Lalanne C, **Ronca V**, Cazzagon N, Bianchi G, Lenzi M, Floreani A, Invernizzi P, Muratori P. Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. *Dig. Liver Dis*. 2018 Mar 2.
8. **Ronca V**, Marco Carbone, Francesca Bemuzzi, Federica Malinverno, Hani S. Mousa, M. Eric Gershwin and Pietro Invernizzi. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. *Expert Review of Clinical Immunology*. 2017 Oct 10.
9. Mousa HS, Carbone M, Malinverno F, **Ronca V**, Gershwin ME, Invernizzi P. Novel therapeutics for primary biliary cholangitis: Toward a disease-stage- based approach. *Autoimmun Rev*. 2016 Sep; 2016 Jul 6
10. Carbone M, **Ronca V**, Bruno S, Invernizzi P, Mells GF. Toward a precision medicine in primary biliary cholangitis. *Dig Liver Dis*. 2016 Aug; 2016 Jun 3.
11. Collaborator : **Ronca V**. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. *Nature Communications* (2015).
12. Collaborator: **Ronca V**. Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study. *American Journal of Gastroenterology*. (2018)
13. Collaborator **Ronca V**. Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients. *Thrombosis and Haemostasis* (2019)

Books:

Unigastro-Book of Gastroenterology. Metal storage disorders. Collaborator: **Ronca V** September 2019

Peer reviewer for scientific journals

- Cellular Physiology and Biochemistry
- PLOS ONE
- Liver International
- Molecular and Cellular Probes
- Digestive and Liver Diseases
- Tissue and Cells
- International Immunopharmacology

Conferences and courses

- IAIHG meeting 1-2 July 2019 Vienna “**Type 2 AIH data under adult hepatologist care**”
- AASLD Emerging Trends in Cholangiopathies: The Dawn of Curative Treatments March 16-17, 2018. Washington USA. **Abstract presenter: *Pre-treatment risk stratification in primary biliary cholangitis: a predictive model to guide first-line combination therapy.***
- AISF Italian Liver Congress. February 2019, Rome, Italy. **Oral Presentation: *Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis***
- AASLD Liver meeting. November 2019, Boston, USA. **Abstract presenter: *Autoantibodies in patients with IL12 β 1 receptor deficiency***
- EASL International Liver Congress. April 2019, Vienna, Austria. **Abstract Presenter *Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis***
- EASL Masterclass (Mezzana Bigli, PV December 3-5, 2015). **Clinical case presenter**
- EASL Clinical School of Hepatology 25-27 November Madrid, Controversies in end-stage liver disease.
- Research methodology course – Level 1. *Siset* (Florence, January 16-17, 2018)
- Research methodology course – advanced level. *Siset* (Florence, September 18-19 2018)

Honours and awards

- Awarded a scholarship merit-based by A.I.L. (Italian association against leukemia) in June 2012.
- EASL Monothematic Conference: Striving towards the elimination of HCV infection. **Travel Grant Winner**
- EASL International liver congress 2018. **Travel Grant Winner**
- AISF Italian Liver congress 2018. **Travel Grant Winner**
- Siica – 5th International conference of translational medicine on pathogenesis and therapy of immunomediated diseases. **EFIS travel grant winner**

Memberships

- Associazione italiana studio fegato (AISF) since 2014.
- European Association for the Study of the Liver (EASL) since 2015
- General Medical Council since March 2019 (number: 7693775)
- Ordine dei Medici di Pavia since March 2015

Certifications

Advanced Course of Clinical Ultrasound in Emergency, Italian Society of Emergency Medicine (SIMEU) (Pinerolo May 2017)

Advanced Life Support, (ALS), International Resuscitation Council (IRC) (Turin, February 2019)

6/6/2020

